Home › Trials › NCT06510816

Investigating ANX007 injections for vision loss in geographic atrophy

A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Phase 3 Interventional Annexon, Inc. · NCT06510816

This study is testing if monthly injections of a new treatment called ANX007 can help people with vision loss from geographic atrophy due to age-related macular degeneration.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment630 (estimated)
Ages50 Years and up
SexAll
SponsorAnnexon, Inc. Industry-sponsored
Locations117 sites (Scottsdale, Arizona and 116 other locations)
Trial IDNCT06510816 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the efficacy and safety of monthly intravitreal injections of ANX007 in patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD). Participants will receive either the active treatment or a sham administration to assess the impact on vision loss. The study is designed to determine if ANX007 can effectively slow down the progression of vision impairment associated with GA. The trial is conducted in multiple locations across California and Arizona.

Who should consider this trial

Good fit: Ideal candidates are individuals diagnosed with geographic atrophy secondary to age-related macular degeneration.

Not a fit: Patients with geographic atrophy caused by conditions other than age-related macular degeneration will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce vision loss for patients with geographic atrophy.

How similar studies have performed: Other studies have shown promise with similar approaches, but the specific efficacy of ANX007 in this context is being investigated for the first time.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of GA of the macula secondary to AMD as determined by the Investigator and confirmed by the independent Central Reading Center.

Exclusion Criteria:

* Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.

NOTE: Other protocol-defined inclusion and exclusion criteria may apply.

Where this trial is running

Scottsdale, Arizona and 116 other locations

+67 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Geographic Atrophy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.